HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
COL1A2
collagen type I alpha 2 chain
Chromosome 7 Β· 7q21.3
NCBI Gene: 1278Ensembl: ENSG00000164692.20HGNC: HGNC:2198UniProt: A0A0S2Z3H5
406PubMed Papers
27Diseases
2Drugs
728Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedHub Gene
RESEARCH IMPACT
Highly StudiedTrendingVariant-Rich
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
extracellular matrixprotease bindingRho protein signal transductionregulation of blood pressureosteogenesis imperfecta type 2osteogenesis imperfecta type 3osteogenesis imperfecta type 4Ehlers-Danlos syndrome, cardiac valvular type
✦AI Summary

COL1A2 encodes the alpha-2 chain of type I collagen, a fibrillar collagen essential for structural integrity of connective tissues 1. Type I collagen comprises two alpha-1 chains and one alpha-2 chain that form triple helices conferring tensile strength to extracellular matrix 2. COL1A2 regulates osteoblast differentiation through histone lactylation-dependent mechanisms and functions in skeletal system development, skin morphogenesis, and blood vessel formation 3. Pathogenic COL1A2 mutations account for approximately 90% of osteogenesis imperfecta (OI) cases 14. Mutations causing qualitative defects (amino acid substitutions, particularly glycine substitutions) typically produce more severe phenotypes than quantitative mutations (null alleles) 5. COL1A2 variants also cause Ehlers-Danlos syndrome subtypes and OI-EDS overlap syndromes, with certain arginine-to-cysteine variants associated with vascular fragility 6. Genotype-phenotype correlations reveal N-terminal mutations are associated with absence of dentinogenesis imperfecta 5. Clinically, bisphosphonate therapy effectively reduces vertebral fractures in OI patients, though long-bone fractures remain frequent 1. Emerging evidence suggests COL1A2 expression in myofibroblasts contributes to pulmonary fibrosis pathogenesis and elevated expression correlates with gastric cancer progression 72.

Sources cited
1
COL1A1 and COL1A2 mutations are the most common cause of osteogenesis imperfecta; bisphosphonates are the primary medical treatment
PMID: 28863000
2
COL1A2 is regulated by histone lactylation in bone mesenchymal stem cells and functions in osteoblast differentiation
PMID: 37752768
3
COL1A2 variants cause osteogenesis imperfecta, Ehlers-Danlos syndrome subtypes, and OI-EDS overlap syndromes with vascular fragility in some cases
PMID: 36896471
4
Approximately 90% of osteogenesis imperfecta cases are due to dominant mutations in COL1A1 and COL1A2 genes
PMID: 30886339
5
Qualitative COL1A2 mutations produce more severe phenotypes than quantitative mutations; N-terminal mutations associated with absence of dentinogenesis imperfecta
PMID: 25944380
6
COL1A2 encodes the alpha-2 chain of type I collagen and is highly expressed in gastric cancer tissues
PMID: 28401451
7
COL1A2-expressing fibroblasts contribute to pulmonary fibrosis myofibroblast activity
PMID: 37142338
Disease Associationsβ“˜27
osteogenesis imperfecta type 2Open Targets
0.85Strong
osteogenesis imperfecta type 3Open Targets
0.83Strong
osteogenesis imperfecta type 4Open Targets
0.83Strong
Ehlers-Danlos syndrome, cardiac valvular typeOpen Targets
0.78Strong
Ehlers-Danlos syndrome, arthrochalasic typeOpen Targets
0.77Strong
osteogenesis imperfecta type 1Open Targets
0.77Strong
combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2Open Targets
0.74Strong
osteogenesis imperfectaOpen Targets
0.70Strong
osteoporosisOpen Targets
0.65Moderate
Ehlers-Danlos syndromeOpen Targets
0.62Moderate
Abnormality of the skeletal systemOpen Targets
0.61Moderate
postmenopausal osteoporosisOpen Targets
0.60Moderate
Dupuytren ContractureOpen Targets
0.59Moderate
Ehlers-Danlos syndrome, classic type, 1Open Targets
0.56Moderate
Ehlers-Danlos syndrome, classic typeOpen Targets
0.53Moderate
genetic disorderOpen Targets
0.51Moderate
Abnormality of the cardiovascular systemOpen Targets
0.51Moderate
Ehlers-Danlos syndrome type 7AOpen Targets
0.47Moderate
Skin ulcerOpen Targets
0.46Moderate
skeletal dysplasiaOpen Targets
0.46Moderate
Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2UniProt
Ehlers-Danlos syndrome, arthrochalasia type, 2UniProt
Ehlers-Danlos syndrome, cardiac valvular typeUniProt
Osteogenesis imperfecta 1UniProt
Osteogenesis imperfecta 2UniProt
Osteogenesis imperfecta 3UniProt
Osteogenesis imperfecta 4UniProt
Pathogenic Variants728
NM_000089.4(COL1A2):c.2206G>T (p.Gly736Cys)Pathogenic
not provided|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|Osteogenesis imperfecta|Osteogenesis imperfecta with normal sclerae, dominant form
β˜…β˜…β˜†β˜†2026β†’ Residue 736
NM_000089.4(COL1A2):c.326G>A (p.Gly109Asp)Pathogenic
Osteogenesis imperfecta type I|Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2|Cardiovascular phenotype|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 109
NM_000089.4(COL1A2):c.1576G>A (p.Gly526Arg)Pathogenic
Osteogenesis imperfecta, perinatal lethal|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2|not provided|Osteogenesis imperfecta type I|Cardiovascular phenotype
β˜…β˜…β˜†β˜†2026β†’ Residue 526
NM_000089.4(COL1A2):c.892G>A (p.Gly298Ser)Pathogenic
Osteogenesis imperfecta|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2
β˜…β˜…β˜†β˜†2026β†’ Residue 298
NM_000089.4(COL1A2):c.1199G>C (p.Gly400Ala)Pathogenic
Ehlers-Danlos syndrome, cardiac valvular type|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1
β˜…β˜…β˜†β˜†2026β†’ Residue 400
NM_000089.4(COL1A2):c.1171G>A (p.Gly391Ser)Pathogenic
Osteogenesis imperfecta with normal sclerae, dominant form|not provided|Dentinogenesis imperfecta|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|Osteogenesis imperfecta|COL1A2-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 391
NM_000089.4(COL1A2):c.2081G>A (p.Gly694Asp)Pathogenic
Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|not provided|Osteogenesis imperfecta type III|Ehlers-Danlos syndrome, cardiac valvular type
β˜…β˜…β˜†β˜†2026β†’ Residue 694
NM_000089.4(COL1A2):c.2755G>A (p.Gly919Ser)Pathogenic
not provided|Cardiovascular phenotype|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|Ehlers-Danlos syndrome, cardiac valvular type;Ehlers-Danlos syndrome, arthrochalasia type;Osteogenesis imperfecta|COL1A2-related disorder|Osteogenesis imperfecta with normal sclerae, dominant form;Osteogenesis imperfecta, perinatal lethal;Osteogenesis imperfecta type III|Ehlers-Danlos syndrome, arthrochalasia type, 2
β˜…β˜…β˜†β˜†2026β†’ Residue 919
NM_000089.4(COL1A2):c.2711G>C (p.Gly904Ala)Likely pathogenic
Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 904
NM_000089.4(COL1A2):c.577G>A (p.Gly193Ser)Pathogenic
not provided|Osteogenesis imperfecta type I|Postmenopausal osteoporosis|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|7 conditions|Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2
β˜…β˜…β˜†β˜†2026β†’ Residue 193
NM_000089.4(COL1A2):c.298G>A (p.Gly100Ser)Pathogenic
Osteogenesis imperfecta type I|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|not provided|Ehlers-Danlos syndrome|COL1A2-related disorder|Cardiovascular phenotype
β˜…β˜…β˜†β˜†2026β†’ Residue 100
NM_000089.4(COL1A2):c.2701G>A (p.Gly901Ser)Pathogenic
not provided|Ehlers-Danlos syndrome|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|COL1A2-related osteogenesis imperfecta|Ehlers-Danlos syndrome, arthrochalasia type, 2
β˜…β˜…β˜†β˜†2025β†’ Residue 901
NM_000089.4(COL1A2):c.1072G>A (p.Gly358Ser)Pathogenic
not provided|Osteogenesis imperfecta, perinatal lethal|Osteogenesis imperfecta type III|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|7 conditions
β˜…β˜…β˜†β˜†2025β†’ Residue 358
NM_000089.4(COL1A2):c.2027G>C (p.Gly676Ala)Pathogenic
not provided|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1
β˜…β˜…β˜†β˜†2025β†’ Residue 676
NM_000089.4(COL1A2):c.389G>A (p.Gly130Asp)Pathogenic
not provided|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I
β˜…β˜…β˜†β˜†2025β†’ Residue 130
NM_000089.4(COL1A2):c.1892G>T (p.Gly631Val)Pathogenic
Osteogenesis imperfecta with normal sclerae, dominant form|Osteogenesis imperfecta type I;Ehlers-Danlos syndrome, classic type, 1|Osteogenesis imperfecta type III
β˜…β˜…β˜†β˜†2025β†’ Residue 631
NM_000089.4(COL1A2):c.1972G>T (p.Gly658Cys)Pathogenic
not provided|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I
β˜…β˜…β˜†β˜†2025β†’ Residue 658
NM_000089.4(COL1A2):c.1009G>A (p.Gly337Ser)Pathogenic
Osteogenesis imperfecta type I|Osteogenesis imperfecta type III|Ehlers-Danlos syndrome, classic type|Osteogenesis imperfecta with normal sclerae, dominant form;Osteogenesis imperfecta type III|not provided|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|Osteogenesis imperfecta|Ehlers-Danlos syndrome, arthrochalasia type, 2|Ehlers-Danlos syndrome|COL1A2-related disorder|Osteogenesis imperfecta with normal sclerae, dominant form
β˜…β˜…β˜†β˜†2025β†’ Residue 337
NM_000089.4(COL1A2):c.2314G>A (p.Gly772Ser)Pathogenic
not provided|Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|Osteogenesis imperfecta with normal sclerae, dominant form|Osteogenesis imperfecta|Ehlers-Danlos syndrome, arthrochalasia type, 2
β˜…β˜…β˜†β˜†2025β†’ Residue 772
NM_000089.4(COL1A2):c.451G>A (p.Gly151Arg)Pathogenic
Ehlers-Danlos syndrome, classic type, 1;Osteogenesis imperfecta type I|COL1A2-related disorder|Osteogenesis imperfecta type I
β˜…β˜…β˜†β˜†2025β†’ Residue 151
View on ClinVar β†—
Drug Targets2
COLLAGENASE CLOSTRIDIUM HISTOLYTICUMApproved
Collagen hydrolytic enzyme
ulcer disease
OCRIPLASMINApproved
Laminin hydrolytic enzyme
Related Genes
SERPINH1Protein interaction100%TGFB1Protein interaction100%COL8A1Protein interaction100%COL10A1Protein interaction100%COL15A1Protein interaction100%THY1Protein interaction100%
Tissue Expression6 tissues
Ovary
100%
Heart
83%
Lung
63%
Liver
6%
Brain
4%
Bone Marrow
1%
Gene Interaction Network
Click a node to explore
COL1A2SERPINH1TGFB1COL8A1COL10A1COL15A1THY1
PROTEIN STRUCTURE
Preparing viewer…
PDB5CTD Β· 1.60 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.34Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.26 [0.20–0.34]
RankingsWhere COL1A2 stands among ~20K protein-coding genes
  • #714of 20,598
    Most Researched406 Β· top 5%
  • #518of 1,025
    FDA-Approved Drug Targets2
  • #63of 5,498
    Most Pathogenic Variants728 Β· top 5%
  • #1,452of 17,882
    Most Constrained (LOEUF)0.34 Β· top 10%
Genes detectedCOL1A2
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
Osteogenesis imperfecta: diagnosis and treatment.
PMID: 28863000
Curr Opin Endocrinol Diabetes Obes Β· 2017
1.00
2
Endothelial Cell-Derived Lactate Triggers Bone Mesenchymal Stem Cell Histone Lactylation to Attenuate Osteoporosis.
PMID: 37752768
Adv Sci (Weinh) Β· 2023
0.90
3
COL1A1 and COL1A2 variants in Ehlers-Danlos syndrome phenotypes and COL1-related overlap disorder.
PMID: 36896471
Am J Med Genet C Semin Med Genet Β· 2023
0.80
4
Genotype-phenotype correlation study in 364 osteogenesis imperfecta Italian patients.
PMID: 30886339
Eur J Hum Genet Β· 2019
0.70
5
DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum.
PMID: 27509835
Osteoporos Int Β· 2016
0.68